Table 3.
Summary of clinicopathologic features, treatment, and outcome of those who failed primary treatment
| Pt's ID |
Age | Histology/Stage | Primary treatment | Outcome of primary treatment | Time to relapse (months) |
Site of Relapse/ progression |
Salvage treatment | Outcome |
|---|---|---|---|---|---|---|---|---|
| 1 | 18 | Choriocarcinoma/ Stage IV |
TAH + BSO + staging op + BEP chemo. |
CR | 4 | Brain | EMA-CO chemo. |
DOD |
| 2 | 25 | Immature teratoma/ Stage Ic |
USO + staging op |
CR | 11 | PAN | BEP chemo | NED at age 33 |
| 3 | 22 | Mixed germ cell tumor/Stage IIIa |
TAH + BSO + staging op + EP chemo |
CR | 12 | Mesentery | EP chemo | NED at age 33 |
| 4 | 19 | EST/Stage IIIa | TAH + BSO + staging op + CP chemo. |
CR | 7 | Mesentery | EP chemo. | NED at age 29 |
| 5 | 29 | EST/Stage IIIc | TAH + BSO + staging op + EP chemo. |
CR | 6 | Pelvic lymph node |
VBP chemo. | NED at age 36 |
| 6 | 65 | Mixed germ cell tumor/Stage IIIc |
TAH + BSO + staging op + EP chemo |
Progressi-on | Liver | Cisplatin + Paclitaxel chemo. |
DOD |
TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; USO, unilateral salpingo-oophorectomy; EMA-CO, etoposide, methotraxate, actinomycin-D, vincristine, and cyclophosphamide; BEP, bleomycin, etoposide, and cisplatin; EP, etoposide and cisplatin; CP, cisplatin and cyclophophamide; VBP, vinblastine, bleomycin, and cisplatin; CR, complete remission; PAN, paraaortic lymph node; DOD, died of disease; NED, no evidence of disease.